OXiGENE Announces Second Quarter 2014 Earnings Conference Call and Webcast

OXiGENE Announces Second Quarter 2014 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer, will report second quarter 2014 results on
Tuesday, August 5, 2014. A conference call and webcast hosted by OXiGENE
management will begin at 4:30 p.m. ET (1:30 p.m. PT).

OXiGENE's earnings conference call can be heard live by dialing (888) 841-3431
in the United States and Canada, and +1 (678) 809-1060 for international
callers, five minutes prior to the beginning of the call.

To listen to a live or archived version of the audio webcast, please log on to
the Company's website, www.oxigene.com. Under the "Investors & Media" tab,
select the link to "Events & Presentations."

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer. The Company is focused on developing vascular
disrupting agents (VDAs), which are compounds that selectively disrupt
abnormal blood vessels associated with solid tumor survival and progression.
The Company's lead clinical product candidate, fosbretabulin (also known as
ZYBRESTAT^®), is in development for solid tumors.OXi4503, its
second-generation product candidate, is in development for acute myeloid
leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property
and therapeutic development expertise to bring life-extending and
life-enhancing medicines to patients.

CONTACT: Investor and Media Contact:
         ir@oxigene.com
         (650) 635-7000

company logo
 
Press spacebar to pause and continue. Press esc to stop.